[go: up one dir, main page]

PE20081385A1 - Derivados de nicotinamida - Google Patents

Derivados de nicotinamida

Info

Publication number
PE20081385A1
PE20081385A1 PE2007001800A PE2007001800A PE20081385A1 PE 20081385 A1 PE20081385 A1 PE 20081385A1 PE 2007001800 A PE2007001800 A PE 2007001800A PE 2007001800 A PE2007001800 A PE 2007001800A PE 20081385 A1 PE20081385 A1 PE 20081385A1
Authority
PE
Peru
Prior art keywords
nicotinamide
piperidin
fluorophenyl
compounds
och3
Prior art date
Application number
PE2007001800A
Other languages
English (en)
Inventor
Tanisha Danielle Rowe Blake
Bruce Cameron Hamper
Wei Huang
Kiefer
Joseph Blair Moon
Bradley E Neal
Kirl Lang Olson
Mattew James Pelc
Barbara Ann Schweitzer
Alti Thorarensen
John I Trujillo
Steve R Turner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20081385A1 publication Critical patent/PE20081385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE NICOTINAMIDA DE FORMULA (I) DONDE R1, R3 Y R4 SON CADA UNO H, F, Cl, CHF2, CF3, OH, CH2OH, ENTRE OTROS; R2 ES H O F; R5 ES H, NH2, OH O CH3; R15 ES H, F, Cl, CH3 U OCH3; L ES C(O)NH, NHC(O) O CH2NHC(O); A ES UN COMPUESTO DE FORMULA (i), EN DONDE n Y m SON CADA UNO 0 O 1; R6 ES H, OH, ENTRE OTROS; R7 ESTA AUSENTE O ES H, F, =O, ENTRE OTROS; R17 ES H O FORMA UN ENLACE PUENTE A TRAVES DEL ANILLO JUNTO CON R6; Q ES ALQUILO(C1-C6), CH2CF3, C(O)CH2CH3, OCH3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 6-(3-FLUOROFENIL)-N-(1-{9-[1-(HIDROXIMETIL)PROPIL]-9H-PURIN-6-IL}PIPERIDIN-4-IL)NICOTINAMIDA, 6-(3-FLUOROFENIL)-N-[1-(1-METIL-1H-TETRAZOL-5-IL)PIPERIDIN-4-IL]NICOTINAMIDA, 6-(3-FLUOROFENIL)-N-{1-[5-(MORFOLIN-4-ILCARBONIL)PIRIDIN-2-IL]PIPERIDIN-4-IL}NICOTINAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROSTAGLANDINA SINTASA DE TIPO HEMATOPOYETICA (H-PGDS) SIENDO UTILES EN EL TRATAMIENTO DE ASMA, RINITIS ALERGICA, DERMATITIS ATOPICA
PE2007001800A 2006-12-19 2007-12-14 Derivados de nicotinamida PE20081385A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87077706P 2006-12-19 2006-12-19
US89165007P 2007-02-26 2007-02-26

Publications (1)

Publication Number Publication Date
PE20081385A1 true PE20081385A1 (es) 2008-10-04

Family

ID=39523704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001800A PE20081385A1 (es) 2006-12-19 2007-12-14 Derivados de nicotinamida

Country Status (10)

Country Link
US (1) US7902373B2 (es)
EP (1) EP2129660A2 (es)
JP (1) JP2010513458A (es)
AR (1) AR064389A1 (es)
CA (1) CA2672373C (es)
CL (1) CL2007003705A1 (es)
PE (1) PE20081385A1 (es)
TW (1) TW200833675A (es)
UY (1) UY30804A1 (es)
WO (1) WO2008075172A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
WO2008104869A1 (en) 2007-02-26 2008-09-04 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2286221A4 (en) 2008-05-13 2011-07-06 Cayman Chem Co METHOD FOR TESTING COMPOUNDS OR MEANS FOR THEIR POSSIBILITY TO DISPLACE STRONG LIGANDS OF THE HEMATOPOIETIC PROSTAGLANDIN D-SYNTHASE
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
KR20130105914A (ko) 2008-09-22 2013-09-26 카이맨 케미칼 컴파니 인코포레이티드 Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도
EP2405812A1 (en) * 2009-03-10 2012-01-18 Koninklijke Philips Electronics N.V. Diagnosis of asthma
WO2010106436A2 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Novel anti-inflammatory agents
CN107875155A (zh) 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
DE112010005848B4 (de) 2010-09-06 2016-03-10 Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences Amidverbindungen
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
BR112014005468A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh derivados de aminopiridina para uso como moduladores de atividade quinase
EP2847181A1 (en) * 2012-05-11 2015-03-18 AbbVie Inc. Pyridazine and pyridine derivatives as nampt inhibitors
WO2014066568A1 (en) 2012-10-24 2014-05-01 Winthrop-University Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CA2949511A1 (en) 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
EP3670522B1 (en) 2014-07-24 2022-01-19 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside chloride
CA2958881A1 (en) * 2014-08-28 2016-03-03 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
EA201790317A1 (ru) 2014-09-10 2018-07-31 Эпизим, Инк. Ингибиторы smyd
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
PL3268379T3 (pl) 2015-03-09 2024-03-18 W.R. Grace & Co. - Conn. Forma krystaliczna rybozydu nikotynamidu
SG11201707263XA (en) 2015-03-31 2017-10-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US11149035B2 (en) * 2017-06-13 2021-10-19 Glaxosmithkline Intellectual Property Dfvelopment Limited Chemical compounds as H—PGDS inhibitors
GB201711234D0 (en) 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US20210139507A1 (en) 2017-12-13 2021-05-13 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h pgds
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
JP7352294B2 (ja) * 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
AU2020242053C1 (en) 2019-03-20 2025-11-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
AU2020282759A1 (en) 2019-05-31 2021-12-23 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CN114466839B (zh) 2019-05-31 2025-01-07 医肯纳肿瘤学公司 Tead抑制剂和其用途
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds
EP4259606A1 (en) * 2020-12-11 2023-10-18 Intervet International B.V. Anthelmintic compounds comprising a pyridine structure
TW202444703A (zh) 2021-09-14 2024-11-16 美商美國禮來大藥廠 Sstr4促效劑鹽
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2249607A1 (en) 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
WO1998027064A1 (en) 1996-12-18 1998-06-25 E.I. Du Pont De Nemours And Company Relatively stable (1,3-disubstitutedimidazol-2-ylidene)-type carbenes
DE19744401A1 (de) 1997-10-08 1999-04-15 Bayer Ag Verfahren zur Herstellung von Triazolinthion-Derivaten
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP4500483B2 (ja) 2002-03-25 2010-07-14 独立行政法人科学技術振興機構 ヒト由来プロスタグランジン合成酵素阻害剤
CA2493883C (en) 2002-07-12 2011-08-30 Japan Science And Technology Agency Drugs for improving the prognosis of brain injury and a method of screening the same
JP4550353B2 (ja) 2002-07-24 2010-09-22 株式会社医薬分子設計研究所 造血器型プロスタグランジンｄ２合成酵素阻害剤
GB2410025B (en) 2002-10-03 2007-03-28 Inst Med Molecular Design Inc Quinazolin-4-one derivatives
EP1575918A2 (en) * 2002-12-19 2005-09-21 Neurogen Corporation Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US20060178403A1 (en) 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
BRPI0412805A (pt) 2003-07-23 2006-09-26 Synta Pharmaceuticals Corp método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
US20080146569A1 (en) 2008-06-19
UY30804A1 (es) 2008-07-31
WO2008075172A2 (en) 2008-06-26
CA2672373A1 (en) 2008-06-26
CA2672373C (en) 2011-08-30
AR064389A1 (es) 2009-04-01
US7902373B2 (en) 2011-03-08
CL2007003705A1 (es) 2008-06-27
JP2010513458A (ja) 2010-04-30
WO2008075172A3 (en) 2008-10-02
TW200833675A (en) 2008-08-16
EP2129660A2 (en) 2009-12-09

Similar Documents

Publication Publication Date Title
PE20081385A1 (es) Derivados de nicotinamida
PE20081779A1 (es) Derivados de nicotinamida
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
PE20110398A1 (es) BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20080061A1 (es) Compuestos derivados de amida como inhibidores de los canales de potasio task-1 y task-3
PE20071236A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
PE20090244A1 (es) Inhibidores de la proteina activadora de la 5-lipoxigenasa (flap)
PE20110928A1 (es) Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
PE20091073A1 (es) Derivados de isoxazolo-piridina
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
PE20090641A1 (es) Amidas heterociclicas
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20061117A1 (es) DERIVADOS DE FENILGLICINAMIDA COMO INHIBIDORES DEL FACTOR VIIa
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR071314A1 (es) Antagonistas de receptor de cgrp
PE20141375A1 (es) Activadores de glucoquinasa
PE20080319A1 (es) Dihidrotienopirimidinas como agentes inhibidores de pde-4

Legal Events

Date Code Title Description
FC Refusal